Emily Lee practices general corporate and securities law, with an emphasis on representing emerging growth companies, venture capital funds and public companies.
Cooley Represents Wheeler Bio in $35M Series A-1 Financing Round
March 20, 2025
Cooley represented Wheeler Bio in the closing of its $35 million Series A-1 financing round. This funding will support Wheeler Bio’s ongoing efforts to expand its capabilities and accelerate the advancement of its partners’ therapies. Lawyers Sale Kwon and Emily Lee led the Cooley team advising Wheeler Bio, a developer of biomanufacturing services designed to translate therapeutic innovations into clinical impact.
Egnyte Announces Majority Investment From GI Partners and TA Associates
February 25, 2025
Cooley advised Egnyte, a provider of secure content collaboration and governance solutions, on its strategic growth investment from GI Partners and TA Associates.
Clay Announces $40 Million Preemptive Series B, $1.25 Billion Valuation
January 22, 2025
Cooley represented Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, in its $40 million preemptive Series B expansion funding at a $1.25 billion valuation.
ArsenalBio Closes Oversubscribed $325 Million Series C
September 4, 2024
Cooley advised Arsenal Biosciences (ArsenalBio), a clinical-stage programmable cell therapy company focused on engineering advanced chimeric antigen receptor T-cell (CAR-T) therapies for solid tumors, on the close of its oversubscribed $325 million Series C financing round.
Cooley advised Clay, a company that helps go-to-market teams up-level their data enrichment and automate personalized outreach, on its $62 million Series B financing, valuing Clay at $500 million.
